2seventy Bio, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.2seventybio.com

Moat Score

Market Cap $257.43M
PE -4
Debt -
Cash $72.87M
EV -
FCF -$85.71M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$57.25M
EBIT	-$57.25M
ROE	-27%
ROA	-12%
FCF	-$85.71M
Equity	$210.81M
Growth Stability	1
PE	-4.5
PB	1.22
P/FCF	-3
P/S	6.8
Price/Cash	0.28
Net Margins	-151%
Gross Margins	100%
Op. Margins	-151%
Sales Growth YoY	-73%
Sales Growth QoQ	-78%
Sales CAGR	-11%
Equity CAGR	38%
Earnings Growth YoY	-66%

Earnings Growth QoQ	97%
Sales CAGR 5Y	-11%
Equity CAGR 5Y	38%
Earnings CAGR 3Y	-11%
Sales CAGR 3Y	-11%
Equity CAGR 3Y	-23%
Market Cap	$257.43M
Revenue	$37.86M
Assets	$479.51M
Cash	$72.87M
Shares Outstanding	51.59M
Moat Score	2%
Working Capital	147.16M
Current Ratio	4.67
Gross Profit	$37.86M
Shares Growth 3y	26%
Equity Growth QoQ	-8%
Equity Growth YoY	-17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

SEC Filings

Direct access to 2seventy Bio, Inc. (TSVT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does 2seventy Bio, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 2seventy Bio, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

2seventy Bio, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for 2seventy Bio, Inc..

Years

Calculation mode

= -$857M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$86M	-$86M	-$86M	-$86M	-$86M	-$86M	-$86M	-$86M	-$86M	-$86M	-$86M	-$857M
DCF		-$78M	-$71M	-$64M	-$59M	-$53M	-$48M	-$44M	-$40M	-$36M	-$33M	-$330M
Value	-$857M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-724%	-48%	-536%	-278%	-217%	-151%	-151%
ROA	-	-	-38%	-39%	-38%	-12%	-12%
ROE	-	-	-81%	-82%	-85%	-27%	-27%

Bad Net Margins (-151.2%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	460%	-78%	68%	10%	-62%	-11%
Earnings YoY growth	-	-63%	143%	-13%	-14%	-74%	-
Equity YoY growth	-	71%	382%	-14%	-18%	-17%	38%
FCF YoY growth	-	-66%	143%	19%	-30%	-53%	-